Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study |
| |
| Authors: | Taylor Sarah A,Rankin Cathryn,Townsend Jeannette J,Craig Johnny B,Vance Ralph B,Solank Dilip L,Brown Thomas D,Jaeckle Kurt Southwest Oncology Group |
| |
| Affiliation: | (1) University of Kansas Medical Center, Kansas City, KS, USA;(2) Southwest Oncology Group Statistical Center, Seattle, WA, USA;(3) University of Utah Medical Center, Salt Lake City, UT, USA;(4) University of Texas Health Science Center at San Antonio, San Antonio, TX;(5) University of Mississippi Medical Center, Jackson, MS, USA;(6) University of Oklahoma Health Science Center, Oklahoma City, OK, USA |
| |
| Abstract: | Amonafide 300 mg/M2 was administeredintravenously on a daily × 5 schedule to 27eligible patients with recurrent orprogressive central nervous system tumors. There were no objective responses. Themost common toxicities weregastrointestinal, hematologic andneurologic. Further study of amonafide inpatients with central nervous systemmalignancies is not indicated. |
| |
| Keywords: | amonafide central nervous system tumors |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
